April 26, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis

Basel, 26 April 2017 New data at AAN reinforce clinical benefit of Roche’s OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis OCREVUS rapidly suppressed signs of disease activity in relapsing MS (RMS) patients In patients with early RMS – recently diagnosed and without prior treatment – OCREVUS was superior to Rebif® (interferon beta-1a) in... Read more

April 25, 2017 Bio/Pharma/CRO Lab Top-10 M&A, Partnerships

MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups

News Release April 25, 2017 Your Contact: Karen Tiano  +1 978 495 0093 Billerica, Massachusetts, April 25, 2017 — MilliporeSigma announced today that the company will sponsor the Startup Program at LabCentral, a biotechnology incubator, in Cambridge, Massachusetts. LabCentral is a private, non-profit organization that provides entrepreneurs and innovative life-sciences startups with lab space and... Read more

April 24, 2017 Bio/Pharma/CRO Clinical Research/Diagn. M&A, Partnerships

United BioPharma selects GE Healthcare’s FlexFactory to build late-stage clinical and commercial production capacity for biopharmaceuticals

CHALFONT ST. GILES, UK and HsinCHu, TAIWAN– 25 April 2017 – United BioPharma Inc. (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform to its new facility focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies in Hsinchu Industrial Park, Taiwan. With this added capacity, UBP will support local healthcare needs by bringing... Read more

April 20, 2017 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10

Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock

Thermo Fisher Scientific Inc. today announced that results from the multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have been published in the May 2017 print issue of Critical Care Medicine. Researchers from the study, titled “Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study,” investigated the use of... Read more

April 19, 2017 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis

Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer

Basel, 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more